Remote Jobs at ImmuneBridge

ImmuneBridge is developing allogeneic immunotherapies for cancer.

Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies.

We are currently pursuing natural killer cell products for hematological malignancies.

Next we will use the unique advantages of our cellular source to tackle solid tumors.

Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood.

Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages.

Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies.

In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells.

Agile Discovery This agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy.

Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line.

This enables rapid iterations of abundant and consistent sources of therapeutic cells.